Key Features

Checkmark

Rapid

Ultrafast turnaround enabling 10 hours DNA to results

Checkmark

Ultrasensitive

Limit of detection down to 0.1% VAF

Checkmark

Affordable

Low sequencing cost

Checkmark

Versatile

Compatible with several sample types

Benefits

  • Comprehensive hematological panel: Detects 254 AML hotspot mutations in 6 genes: FLT3, DNMT3A, IDH1, IDH2, KIT, and NPM1
  • Fast workflow: from DNA to results in 10 hours, including 3.5 hours of hands-on time
  • User-friendly data analysis software with a graphical user interface enabling FASTQ-to-variant reports in minutes
  • Compatible with 10-500 ng DNA from whole blood or bone marrow lysate (AML Panel), 1 tube of reaction
  • Nanopore sequencing panel: Compatible with MinION and Flongle flow cells
  • Requires only 30 minutes of sequencing time on MinION for up to 24 samples per run

Customer Testimonial

I have long been looking for a solution to take advantage of the rapid turnaround time of the Oxford Nanopore platform to benefit cancer patients. The VarMap™ Acute Myeloid Leukemia (AML) Nanopore Panel uniquely enables accurate detection and quantitation of low-level mutations in less than 10 hours. I am very impressed and hope to introduce NuProbe to more researchers.

 

–Thidathip Wongsurawat, PhD., University of Arkansas for Medical Sciences

List of Mutations

GeneAA mutationCDS mutation
FLT3p.D835Hc.2503G>C
p.D835Nc.2503G>A
p.D835Yc.2503G>T
p.D835Ac.2504A>C
p.D835Vc.2504A>T
p.D835Ec.2505T>A
p.D835Ec.2505T>G
p.I836Fc.2506A>T
p.I836Lc.2506A>C
p.I836Vc.2506A>G
p.I836Dc.2506_2507delATinsGA
p.I836Hc.2506_2507delATinsCA
p.I836Mc.2508C>G
DNMT3Ap.R882Cc.2644C>T
p.R882Gc.2644C>G
p.R882Sc.2644C>A
p.R882Hc.2645G>A
p.R882Lc.2645G>T
p.R882Pc.2645G>C
IDH1p.R132Cc.394C>T
p.R132Gc.394C>G
p.R132Sc.394C>A
p.R132Hc.395G>A
p.R132Lc.395G>T
p.R132Pc.395G>C
IDH2p.R140Gc.418C>G
p.R140Wc.418C>T
p.R140Lc.419G>T
p.R140Qc.419G>A
p.R172Kc.515G>A
p.R172Mc.515G>T
p.R172Sc.515G>C
KITp.D816Hc.2446G>C
p.D816Yc.2446G>T
p.D816Ic.2446_2447delGAinsAT
p.D816Vc.2447A>T
NPM1p.W288fs*12c.863_864insTCTG
p.W288fs*12c.863_864insCATG
p.W288fs*12c.863_864insCCTG

Sample Data

Minimum Residual Disease
  • Horizon Myeloid reference sample (HD829) – 15,000 haploid copies ~ 50 ng was tested using the VarMap AML panel.
  • 100% concordance in variant calling.
AML Mutation Detection
  • Summary of VarMap nanopore results for 25 clinical cancer samples (7 fresh/frozen, 18 FFPE).
  • Relative to the NGS results, VarMap had a sensitivity of 100 % and a specificity of 99%.
  • The numbers in quadrant display the number of loci in each group. Purple dots represent variants that passed the variant call filter. 22/23 variant calls below NGS sensitivity were confirmed by ddPCR.

Workflow

Workflow Step 1

Step 1: DNA Extraction

DNA is extracted from clinical samples with commercial extraction kits such as QIAamp® DNA Blood Mini Kit.
40 min (40 min hands-on)

Blocker Icon

Step 2: BDA Reaction

NuProbe’s kit reagents and clinical samples are prepared for BDA reactions.

2.5 hrs ( 30 min hands-on)

AML Steps

STEP 3: Adapter attachment PCR

BDA products are amplified and adapters are attached.

1.5 hrs (30 min hands-on)

AML Steps

STEP 4: Amplicon Assembly

Amplicons are assembled to generate high-quality long DNA for nanopore sequencing

3 hrs (30 min hands-on)

AML Steps

STEP 5: Nanopore Sequencing

Oxford Nanopore’s Ligation sequencing kit (SQK-LSK109) is used for library preparation for nanopore sequencing on MinION

3 hrs (2 hrs hands-on)

Computer Analysis Icon

STEP 6: Data Analysis

NuProbe’s user-friendly analysis software analyzes demultiplexed FASTQ files to generate a Variant Analysis Report that reports all detected variants, the quality scores for the detected variants, and genomic locations.

(10 – 15 min per sample)

Download Product User Manual

    Compatible Instruments

    Nanopore Instruments

    Oxford Nanopore Flongle

    Oxford Nanopore Flongle


    Oxford Nanopore MinION

    Oxford Nanopore MinION


    Oxford Nanopore GridION

    Oxford Nanopore GridION

    Request Quote / Demo

    For research use only. Not for use in diagnostic procedures.

    In patients with Acute Myeloid Leukemia (AML), several genes are frequently mutated, including FLT3, IDH1, IDH2, DNMT3A, KIT, and NPM1. The presence of these specific mutations can guide treatment with targeted therapies such as RYDAPT® (midostaurin), XOSPATA® (gilteritinib), TIBSOVO® (ivosidenib), and IDHIFA® (enasidenib).

    The VarMap™ AML Nanopore Panel enables highly sensitive mutation detection and quantitation for AML patients. The kit uses NuProbe’s PCR-based Blocker Displacement Amplification (BDA) technology to enable the selective amplification of low abundant sequence variants (SNV and indels) in a background of wildtype DNA. Following PCR enrichment, Nanopore sequencing is applied to reveal the identity of the variants.

    Deepak Thirunavukarasu, Ph.D., serves as Scientist at Nuprobe. He obtained his Doctorate degree from State University of New York at Albany and has over 5 years of research experience in nucleic acid technology, genomics and sequencing.

    Fill in the form below to contact Deepak for questions about the VarMap Nanopore products.

    Request Quote / Demo


      Quantity (if requesting a quote)